Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | NQO2 | P16083 | 4/20 | 0.53 |
| ▸ | HTR6 | P50406 | 2/20 | 0.51 |
| ▸ | MTNR1A | P48039 | 5/20 | 0.49 |
| ▸ | AKR1C3 | P42330 | 4/20 | 0.49 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4908501 | 0.90 | HTR6 (0.55) | LMNANQO2HTR6MTNR1AMTNR1B | |
| SCHEMBL4900804 | 0.83 | LMNA (0.54) | LMNAAKR1C3TP53ALDH1A1MAPT | |
| SCHEMBL4903791 | 0.81 | LMNA (0.61) | LMNAAKR1C3TP53ALDH1A1MAPT | |
| SCHEMBL8858490 | 0.79 | NQO2 (0.68) | LMNANQO2HTR6MTNR1AAKR1C3 | |
| SCHEMBL4902642 | 0.76 | LMNA (0.60) | LMNAAKR1C3TP53POLBALDH1A1 | |
| SCHEMBL4906975 | 0.75 | LMNA (1.00) | LMNATP53KDM4EHPGDPOLB | |
| SCHEMBL4899808 | 0.74 | LMNA (0.56) | LMNAAKR1C3TP53POLBALDH1A1 | |
| SCHEMBL4906494 | 0.74 | LMNA (0.56) | LMNATP53KDM4EPKMHPGD | |
| SCHEMBL4904168 | 0.74 | LMNA (0.56) | LMNATP53KDM4EHPGDPOLB | |
| SCHEMBL8883022 | 0.74 | NQO2 (0.61) | NQO2HTR6MTNR1ATP53ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080090829-A1 | SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS | PFIZER INC. | 2008-04-17 | — | — | US | disclosed |
| US-20080090829-A1 | SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS | PFIZER INC. | 2008-04-17 | — | — | US | disclosed |
| US-20080090829-A1 | SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS | PFIZER INC. | 2008-04-17 | — | — | US | disclosed |
| US-20060229363-A1 | Substituted Heteroaryl- and Phenylsulfamoyl Compounds | HAMANAKA ERNEST S | 2006-10-12 | — | — | US | disclosed |
| US-20050288340-A1 | Substituted heteroaryl- and phenylsulfamoyl compounds | PFIZER INC | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229363-A1 | Substituted Heteroaryl- and Phenylsulfamoyl Compounds | PPARA, PPARG, PPARD | LMNA 317/4885NQO2 2080/4885HTR6 1188/4885 |
| US-20050288340-A1 | Substituted heteroaryl- and phenylsulfamoyl compounds | PPARA, PPARG, PPARD | LMNA 319/4885NQO2 2277/4885HTR6 1162/4885 |
| US-20080090829-A1 | SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS | PPARA, PPARG, PPARD | LMNA 319/4885NQO2 2277/4885HTR6 1162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.